Coral Mourino

Vigo, GA, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality.

Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality.

Journal: Lupus science & medicine
Published: August 06, 2025

Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes.

Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes.

Journal: Arthritis research & therapy
Published: November 26, 2024

Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?

Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?

Journal: Rheumatology (Oxford, England)
Published: January 16, 2024

Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus.

Novel endothelial progenitor cells populations as biomarkers of damage and remission in systemic lupus erythematosus.

Journal: Arthritis research & therapy
Published: January 11, 2024

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Journal: Lupus science & medicine
Published: October 19, 2023

Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.

Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.

Journal: Rheumatology (Oxford, England)
Published: August 24, 2023

Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.

Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.

Journal: Frontiers in immunology
Published: August 14, 2023

Semaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner.

Semaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner.

Journal: Frontiers in immunology
Published: July 27, 2023

Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

Journal: Rheumatology (Oxford, England)
Published: December 16, 2022

Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest.

Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest.

Journal: Clinical biochemistry
Published: March 21, 2017

Correction: CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.

Correction: CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.

Journal: PloS one
Published: September 29, 2015

CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.

CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.

Journal: PloS one
Published: March 27, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026